13 studies found for:    IL-2 SELECT
Show Display Options
Rank Status Study
1 Active, not recruiting The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma
Condition: Metastatic Renal Cell Carcinoma
Intervention: Drug: aldesleukin (Proleukin)
2 Recruiting IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma
Condition: Malignant Melanoma
Intervention: Other: Observation
3 Completed
Has Results
A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept;   Drug: Methotrexate;   Drug: Placebo
4 Recruiting Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
Conditions: Rheumatoid Arthritis;   Ankylosing Spondylitis;   Systemic Lupus Erythematosus;   Psoriasis;   Behcet's Disease;   Wegener's Granulomatosis;   Takayasu's Disease;   Crohn's Disease;   Ulcerative Colitis;   Autoimmune Hepatitis;   Sclerosing Cholangitis
Intervention: Drug: Interleukin 2
5 Completed Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
Condition: Malignant Melanoma
Intervention: Drug: HSPPC-96 or Oncophage
6 Completed
Has Results
Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People
Condition: HIV Infections
Intervention: Drug: IL-2
7 Completed
Has Results
An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy
Condition: HIV Infections
Intervention: Drug: Recombinant interleukin-2 (rIL-2)
8 Completed
Has Results
Anti-Tac for Treatment of Leukemia
Conditions: HTLV-I Infection;   T Cell Leukemia
Intervention: Biological: daclizumab
9 Recruiting Therapy for Children With Advanced Stage Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: cyclophosphamide;   Drug: topotecan;   Biological: hu14.18K322A;   Procedure: peripheral blood stem cell harvest;   Procedure: surgical resection;   Drug: cisplatin;   Drug: etoposide;   Drug: doxorubicin;   Drug: vincristine;   Drug: busulfan;   Drug: melphalan;   Biological: peripheral blood stem cell transplantation;   Biological: natural killer cell infusion;   Radiation: radiation therapy;   Biological: GM-CSF;   Biological: G-CSF;   Drug: mesna;   Drug: levetiracetam;   Biological: interleukin-2;   Drug: Isotretinoin
10 Unknown  Immunochemotherapy for Metastatic Renal Cell Carcinoma
Condition: Adenocarcinoma Clear Cell
Intervention: Drug: Capecitabine (Xeloda)
11 Recruiting Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study
Condition: Non Resectable Stage III or Stage IV Malignant Melanoma
Interventions: Other: Intradermal Autologous DC Vaccine + RT;   Other: Intradermal Autologous DC Vaccine + IFN-alfa;   Other: Intradermal Autologous Dendritic Cell Vaccine + radiotherapy + IFN-alfa;   Biological: only Intradermal Autologous DC Vaccine
12 Completed A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors
Condition: Lung Cancer, Non-Small Cell
Interventions: Drug: Pazopanib (GW786034);   Drug: Gemcitabine;   Drug: Cisplatin
13 Completed Effects of Anesthetic Technique on Immune and Inflammatory Systems Following Radical Prostatectomy
Condition: Prostate Cancer
Interventions: Drug: Patient controlled analgesia (PCA);   Drug: Thoracic Epidural Analgesia (TEA)

Indicates status has not been verified in more than two years